Noncoding Ribonucleic Acids (RNAs) May Improve Response to Immunotherapy in Pancreatic Cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with over 90% mortality shortly after diagnosis.
• Immune checkpoint inhibitors (ICIs) show limited efficacy in PDAC, unlike in other cancers.
• Noncoding RNAs (ncRNAs) are increasingly recognized for their role in PDAC cell-immune cell interactions and immune evasion.

Purpose of the Study:

• To comprehensively review the multifaceted roles of ncRNAs in mediating immune evasion in PDAC.
• To explore how ncRNAs influence immune cell function and PDAC progression.
• To discuss the potential of ncRNAs in overcoming ICI resistance and monitoring the PDAC immune microenvironment.

Main Methods:

• Literature review of recent findings on ncRNAs in PDAC immunology.
• Analysis of mechanisms by which PDAC cells utilize ncRNAs to modulate immune cells (macrophages, dendritic cells, NK cells, T cells).
• Examination of ncRNAs' impact on immune checkpoint protein expression and T cell cytotoxicity.

Main Results:

• PDAC cells manipulate ncRNAs (e.g., miR-301a, miR-340, miR-203, miR-146a, miR-212-3p, miR-4299, miR-153) to alter immune cell phenotypes and functions, promoting immune evasion.
• Specific ncRNAs (e.g., AL137789.1, hsa_circ_0046523, LINC00460, miR-155-5p) are upregulated by PDAC cells to enhance immune checkpoint proteins and escape T cell-mediated killing.
• ncRNAs from suppressive immune cells can also promote PDAC cell proliferation, invasion, and drug resistance.

Conclusions:

• ncRNAs are key mediators of immune evasion in PDAC, impacting various immune cell types and functions.
• Targeting ncRNAs presents a promising therapeutic avenue to overcome ICI resistance in PDAC.
• ncRNAs hold potential as biomarkers for monitoring the PDAC immune microenvironment and predicting ICI response.